-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

3545 Long-Term Outcomes and Late Complications of Allogeneic Stem Cell Transplant with CD34+ Positive Selection in Adults with Acute Leukaemia and Myelodysplastic Syndrome: A Single-Centre Study

Program: Oral and Poster Abstracts
Session: 723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence: Poster II
Hematology Disease Topics & Pathways:
Research, Clinical Research, Real-world evidence
Sunday, December 8, 2024, 6:00 PM-8:00 PM

Elisa Roldan, MD1,2*, Alba Puyuelo, MD3,4*, Sergi Camarillas, MD5*, Olga Salamero, MD4,6,7*, Ana Perez Gonzalez, MD8,9*, Maria Laura Fox, MD10,11*, Felix Lopez, MD12*, Maria Sola, MD13*, Pere Barba, MD14,15,16, Guillermo Orti, MD, PhD17* and David Valcarcel, MD, PhD6,10

1Autonomous University of Barcelona., Barcelona, Spain
2Sheffield Teaching Hospitals NHS Foundation Trust. Sheffield, United Kingdom, Sheffield, United Kingdom
3Vall D'Hebron University Hospital, Hematology Department, Barcelona, Spain
4Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
5Vall d'Hebron University Hospital, Barcelona, Spain
6Department of Hematology, Vall d’Hebron University Hospital, Barcelona, Spain
7Hematology Department, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
8Department of Hematology, Experimental Hematology Unit, Vall d’Hebron Institute of Oncology (VHIO), University Hospital Vall d’Hebron, Barcelona, Barcelona, Spain
9Vall d´Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d’Hebrón, Barcelona, Spain
10Experimental Hematology Unit, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
11Hematology Department, Vall d'Hebron University Hospital, University Autònoma of Barcelona (UAB), Barcelona, Spain
12Vall D'Hebron Universitary Hospital, Barcelona, Spain
13Department of Hematology, Experimental Hematology Unit, Vall d’Hebron Institute of Oncology (VHIO), University Hospital Vall d’Hebron, Barcelona, Spain
14Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain
15Vall d’Hebron Institute of Oncology (VHIO), Department of Hematology, University Hospital Vall d'Hebron, Universitat Autònoma of Barcelona (UAB), Barcelona, Spain
16Department of Hematology, Hospital Universitari Vall d'Hebron, Barcelona, Spain
17Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain

INTRODUCTION:

Ex vivo T cell depletion (TCD) by CD34+ selection (CD34+s) significantly reduces acute and chronic graft-versus-host disease (GVHD) without increasing relapse in hematological malignancies but raises infection rates. Long-term outcomes and late complications of this approach are under-documented.

METHODS:

We retrospectively analyzed data from 2016 to 2022 for patients undergoing CD34+s allogeneic stem cell transplant (alloSCT) at Vall d’Hebron Hospital, Spain, for acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), or myelodysplastic syndrome (MDS), with a minimum 12-month follow-up. The CD34+s alloSCT platform combined ex vivo CD34+s and in vivo TCD with ATG 5-7.5 mg/kg. Conditioning regimens included myeloablative (MAC) with total body irradiation 12 Gy, thiotepa 10 mg/kg, and cyclophosphamide 120 mg/kg (TBI-TT-Cy) for fit, young patients (≤50 years) and reduced intensity (RIC) with fludarabine 125 mg/m2, busulfan 9.6 mg/kg, and melphalan 140 mg/m2(Flu-Bu-Mel). No post-transplant immunosuppressive therapy was planned. Informed consent was obtained from all patients. We used Stata/BE 17.0 for univariate analysis of categorical and continuous variables, bivariate analysis with classical hypothesis tests, and survival analysis with Kaplan-Meier and log-rank tests.

RESULTS:

Median follow-up of the study was 29.3 months [0.8-97.4]. Eighty-eight patients were included: 53.4% female, median age 50.5 [18-71]. Most had AML (62.5%), followed by ALL (18.2%) and MDS (19.3%), with high-risk disease (70.5%) and 41.9% with more than one prior treatment. Unrelated donors were used in 70.4%, with 59% full match. MAC was used in 48.9%. Previous comorbidities: 14.8% respiratory, 13.7% endocrine, 5.7% autoimmune, 4.6% chronic liver, 2.27% chronic kidney, and one cardiovascular case. The median HCT-CI score was 2 [0-9].

Two patients experienced graft failure (2.3%, one primary and one secondary), with median engraftment at 12 days [8-22], similar in both MAC (11) and RIC (12). Acute GVHD occurred in 23.9% (4.5% grade ≥3) and chronic GVHD in 3.4% (only one severe). Infections were frequent: 55.4% had ≥3 infections requiring antibiotics or admission in one year, 61.4% had CMV reactivation, 17% EBV requiring rituximab, 18.2% BK virus, and 9% adenovirus.

Late complications in 49 patients alive >1 year post-transplant included gonadal dysfunction (23.8% males, 28% females), thyroid disease (14%), respiratory disease (28.6%), osteopenia (36.7%), osteoporosis (20.4%), cataracts (12.2%) and iron overload (12.2%). Secondary malignancies were noted in 12.2% (4 solid tumors, 2 hematological). Avascular necrosis was not found.

New cardiovascular risk factors were seen in 59.1% of the patients. Dyslipidemia was the most common (18%), followed by metabolic syndrome (16.3%), hypertension (14%), type 2 diabetes (8.1%), and abnormal echocardiogram (8.1%). Heart failure was diagnosed in only one patient, and none had ischemic cardiac disease.

Engraftment was sustained, with only 20% requiring hematopoietic support at 12 months (18% erythropoietin (EPO), 8% G-CSF, 8% eltrombopag), reducing to 6.4% at 2 years (needing only EPO). Lymphopenia was present in 34% of patients at 12 months and decreased over time to 6.4% at 2 years, 2.5% at 3 years, and 0% at 4 years. Immune reconstitution steadily improved. Over the same time points (12 months, 2 years, 3 years, and 4 years), low CD4+ lymphocytes dropped from 62% to 26.7%, 14.3%, and 0%. Low NK cells decreased from 6% to 4.4% and 0%. CD19 lymphopenia fell from 20% to 11.1% and 0%.

Female hypogonadism was significantly higher in MAC (93.3%) vs RIC (6.7%) (p=0.008). No other significant differences were found between MAC and RIC.

Overall survival (OS) was 55% at 3y, higher in MAC (65.1%) than RIC (45.2%) (p=0.02). Relapse occurred in 27.2% of patients, with 70.4% still in complete remission. Relapse was the most common cause of death, followed by infections. Progression-free survival (PFS) at 3y was 69.9% (MAC 75.9% vs. RIC 63.3%, p=0.25). Non-relapse mortality (NRM) was 23.4% at 3y, higher in RIC (30.6% vs. 15.9%, p=0.04). GVHD-free survival was 93.9% at 3y (100% RIC vs. 89.6% MAC, p=0.14). GVHD and relapse-free survival (GRFS) was 64% at 3y (MAC 65%, RIC 63.3%, p=0.63).

CONCLUSION:

The CD34+s alloSCT platform offers good long-term outcomes with low GVHD rates and high GRFS, indicating a good quality of life for survivors one year post-transplant.

Disclosures: Roldan: Janssen (UK): Honoraria, Other: Travel , Speakers Bureau. Puyuelo: MSD: Honoraria; Novartis: Honoraria. Perez Gonzalez: Astellas Pharma: Honoraria; AbbVie: Honoraria. Fox: Novartis: Honoraria, Other: Travels and grants. Barba: Autolus: Consultancy; Kite-Gielead: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; Pfizer: Honoraria; Incyte: Honoraria; BMS: Honoraria. Orti: Jazz: Honoraria; Incyte: Honoraria, Research Funding; Novartis: Honoraria; Pfizer: Honoraria; Sanofi: Honoraria.

*signifies non-member of ASH